Real Endpoints, the leading market-access platform and advisory firm, announces that four biopharma companies with combined 2022 sales of nearly $8 billion have signed contracts to offer Real Endpoint's RE Assist tool to support Medicare patients in need of deductible and copay assistance. RE Assist provides actionable, comprehensive foundation fund information in a compliant and easy to navigate format.
read full article ›